AstraZeneca to harmonize global listing structure

AstraZeneca (AZN) plans to harmonize its share listing structure to deliver a global listing for global investors in a global company. The Board of AstraZeneca is recommending to shareholders a Harmonized Listing Structure for the company’s ordinary shares across the London Stock Exchange, Nasdaq Stockholm and the New York Stock Exchange. This requires upgrading AstraZeneca’s existing U.S. equity listing by way of a direct listing of AstraZeneca ordinary shares on the NYSE, replacing the existing U.S. listing of AstraZeneca ADRs on Nasdaq. Following implementation of the Harmonized Listing Structure, shareholders will be able to trade their interests in AstraZeneca ordinary shares across the LSE, STO and NYSE. Michel Demare, Chair, AstraZeneca said: “Today we set out our proposed harmonized listing structure which will support our long-term strategy for sustainable growth, while remaining headquartered in the UK and listed in London, Stockholm and New York. Enabling a global listing structure will allow us to reach a broader mix of global investors and will make it even more attractive for all our shareholders to have the opportunity to participate in AstraZeneca’s exciting future.”